A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations

Trial ID or NCT#

NCT00186433

Status

not recruiting iconNOT RECRUITING

Purpose

1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC). 2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors both in endemic and non-endemic areas. 3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for both endemic and non-endemic patient populations.

Official Title

A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations

Eligibility Criteria

Ages Eligible for Study: Older than 18
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Having a new diagnosis of Nasopharyngeal carcinoma.* Being treated with either radiotherapy or chemoradiotherapy for this condition.
Exclusion Criteria:
  1. * Age \<18 since NPC is a very rare condition in this age group and may have a different biological behavior* Patients who are unable to provide informed consents for themselves.
View All Criteria
Show Less

Investigator(s)

Quynh-Thu Le, MD, FACR, FASTRO, FARS
Quynh-Thu Le, MD, FACR, FASTRO, FARS
Radiation oncologist
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)

Contact us to find out if this trial is right for you.

Contact

Quynh-Thu Le
650-498-6184

View on ClinicalTrials.gov